GlassScriptPhysician profile
Jay S Rosen
NPI 1326032822
$12,915.78
in general payments reported to CMS, 2019-2025
28 companies · $2,064 in 2025
The $2,064 reported for 2025 was more than what 97% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,673 · 2020: $1,040 · 2021: $1,844 · 2022: $2,141 · 2023: $1,569 · 2024: $2,585 · 2025: $2,064.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,101 · Entertainment: $116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,101.26 |
| Entertainment | $116.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $2,431.41 | 2021-2025 | Omni Surgical System, Tearcare System |
| Bausch & Lomb Americas INC. | $2,205.01 | 2022-2025 | Miebo, Xiidra, Infuse |
| Alcon Vision LLC | $1,657.74 | 2019-2025 | Total30, Simbrinza, Rhopressa |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $1,354.53 | 2019-2021 | |
| Biotissue Holdings INC. | $593.23 | 2024-2025 | |
| Coopervision INC. | $591.55 | 2019-2025 | Myday Contact Lens, Misight Contact Lens |
| Abbvie INC. | $553.76 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $423.56 | 2020-2023 | Cequa |
| Johnson & Johnson Vision Care, INC. | $405.02 | 2019-2025 | Acuvue |
| Dompe US, INC. | $369.90 | 2021-2024 | Oxervate |
| Optos, INC. | $320.91 | 2019-2023 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Ocular Therapeutix, INC. | $284.37 | 2019-2025 | Dextenza |
| Johnson & Johnson Surgical Vision, INC. | $280.80 | 2019-2022 | |
| Allergan, INC. | $236.52 | 2020-2022 | |
| Kala Pharmaceuticals, INC. | $227.95 | 2019-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $224.90 | 2024-2025 | Xdemvy |
| Maculogix, INC. | $210.72 | 2019-2020 | |
| Glaukos Corporation | $161.61 | 2022-2025 | Idosetr, Istent Infinite |
| Rxsight INC | $116.31 | 2024 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Contact Lens |
| Optovue, INC. | $90.33 | 2019 | |
| Harrow Eye, LLC | $36.19 | 2024-2025 | Vevye |
| Visionix USA, INC | $35.18 | 2022 | |
| Oyster Point Pharma, INC. | $23.01 | 2022 | |
| Apyx Medical Corporation | $20.88 | 2020 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Novartis Pharmaceuticals Corporation | $17.32 | 2021 | |
| Eyevance Pharmaceuticals LLC | $15.87 | 2022 | |
| Abb Con-Cise Optical Group LLC | $7.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Rosen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.